ArticleNeuromolecular medicine2026
Curculigoside Alleviates CSDS-induced Depressive-like Behavior by Modulating Pyramidal Neuron Excitability and Synaptic Transmission.
Article in Neuromolecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Curculigoside (CUR), a flavonoid derived from traditional Chinese medicine, has shown potential in alleviating depressive symptoms. However, the mechanisms underlying its antidepressant effects remain unclear. The aim of this study was to investigate the effect of CUR on depressive-like behavior in the chronic social defeat stress (CSDS) model and its potential mechanism of action on pyramidal neuronal excitability and synaptic transmission. We injected 20 mg/kg of CUR intraperitoneally for seven days and found that CUR significantly alleviated emotional deficits in mice subjected to CSDS. CUR restored the activity of pyramidal neurons in the medial prefrontal cortex (mPFC) and ventral CA1 (vCA1) regions, which were suppressed by CSDS during depression-like behaviors. Through network pharmacology and molecular docking, we identified CUR's pharmacological targets and found that its antidepressant effects are partly mediated by modulating the cAMP-PKA signaling pathway. CUR treatment ameliorated synaptic transmission dysfunction in both the mPFC and vCA1. CUR regulated the cAMP-PKA signaling pathway and GluA1 subunit trafficking, thereby contributing to the restoration of synaptic function. CUR alleviated depression-like behaviors induced by CSDS by modulating the excitability and synaptic transmission of pyramidal neurons in the mPFC and vCA1 through activation of the cAMP-PKA-GluA1 signaling pathway. These findings provide new insights into CUR's antidepressant mechanisms and highlight its potential as a therapeutic agent for depression.
Indexed as
Identifiers
42360548What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.